JP2018500560A5 - - Google Patents

Download PDF

Info

Publication number
JP2018500560A5
JP2018500560A5 JP2017532050A JP2017532050A JP2018500560A5 JP 2018500560 A5 JP2018500560 A5 JP 2018500560A5 JP 2017532050 A JP2017532050 A JP 2017532050A JP 2017532050 A JP2017532050 A JP 2017532050A JP 2018500560 A5 JP2018500560 A5 JP 2018500560A5
Authority
JP
Japan
Prior art keywords
skin
patient
jun
phosphorylated
clathrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017532050A
Other languages
English (en)
Japanese (ja)
Other versions
JP6903577B2 (ja
JP2018500560A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/065767 external-priority patent/WO2016100308A1/en
Publication of JP2018500560A publication Critical patent/JP2018500560A/ja
Publication of JP2018500560A5 publication Critical patent/JP2018500560A5/ja
Priority to JP2021068271A priority Critical patent/JP2021113819A/ja
Application granted granted Critical
Publication of JP6903577B2 publication Critical patent/JP6903577B2/ja
Priority to JP2022198375A priority patent/JP2023036694A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017532050A 2014-12-16 2015-12-15 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法 Active JP6903577B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2021068271A JP2021113819A (ja) 2014-12-16 2021-04-14 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
JP2022198375A JP2023036694A (ja) 2014-12-16 2022-12-13 皮膚におけるｃ－Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462092531P 2014-12-16 2014-12-16
US62/092,531 2014-12-16
PCT/US2015/065767 WO2016100308A1 (en) 2014-12-16 2015-12-15 Methods for measurement of inhibition of c-jun n-terminal kinase in skin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021068271A Division JP2021113819A (ja) 2014-12-16 2021-04-14 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法

Publications (3)

Publication Number Publication Date
JP2018500560A JP2018500560A (ja) 2018-01-11
JP2018500560A5 true JP2018500560A5 (https=) 2019-01-31
JP6903577B2 JP6903577B2 (ja) 2021-07-14

Family

ID=56110930

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017532050A Active JP6903577B2 (ja) 2014-12-16 2015-12-15 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
JP2021068271A Pending JP2021113819A (ja) 2014-12-16 2021-04-14 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
JP2022198375A Pending JP2023036694A (ja) 2014-12-16 2022-12-13 皮膚におけるｃ－Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2021068271A Pending JP2021113819A (ja) 2014-12-16 2021-04-14 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
JP2022198375A Pending JP2023036694A (ja) 2014-12-16 2022-12-13 皮膚におけるｃ－Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法

Country Status (5)

Country Link
US (2) US9513297B2 (https=)
EP (1) EP3233808B1 (https=)
JP (3) JP6903577B2 (https=)
ES (1) ES2882954T3 (https=)
WO (1) WO2016100308A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9139534B2 (en) * 2011-04-22 2015-09-22 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
CN107108524A (zh) 2014-12-16 2017-08-29 西格诺药品有限公司 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107922287B (zh) 2015-07-24 2021-04-09 细胞基因公司 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
WO2024097940A1 (en) * 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Therapy for the treatment of cancer

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH549339A (de) 1971-05-12 1974-05-31 Ciba Geigy Ag Herbizides mittel.
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
ATE288420T1 (de) 1999-06-09 2005-02-15 Yamanouchi Pharma Co Ltd Neuartige heterocyclische carboxamid-derivate
WO2000076980A1 (en) 1999-06-10 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Novel nitrogen-contaiing heterocyclic derivatives or salts thereof
BR0013551A (pt) 1999-08-13 2003-06-17 Vertex Pharma Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003082855A1 (en) 2002-03-28 2003-10-09 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
EP1518855B1 (en) 2002-06-28 2011-10-26 Astellas Pharma Inc. Diaminopyrimidinecarboxa mide derivative
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
JPWO2004054617A1 (ja) 2002-12-13 2006-04-20 協和醗酵工業株式会社 中枢疾患の予防および／または治療剤
US20040242613A1 (en) 2003-01-30 2004-12-02 Boehringer Ingelheim Pharmaceuticals, Inc. Pyrimidine derivatives useful as inhibitors of PKC-theta
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
RU2006107578A (ru) 2003-09-24 2007-10-27 Вайет Холдингз Корпорейшн (Us) 6-арилпиримидин, применяемый в качестве противоракового агента
WO2005095382A1 (ja) 2004-03-30 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. 抗腫瘍剤
JP2008505910A (ja) 2004-07-08 2008-02-28 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Ｐｋｃ−シータのインヒビターとして有用なピリミジン誘導体
JP2008512429A (ja) 2004-09-10 2008-04-24 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング ロフルミラストとｓｙｋインヒビターとの組合せ物並びにその使用方法
CA2579007A1 (en) 2004-09-10 2006-03-16 Altana Pharma Ag Ciclesonide and syk inhibitor combination and methods of use thereof
JP2006124387A (ja) 2004-09-30 2006-05-18 Taisho Pharmaceut Co Ltd 新規なキノリン、テトラヒドロキナゾリン、及びピリミジン誘導体と、これらを使用することに関連した治療方法
JP5046943B2 (ja) 2004-09-30 2012-10-10 テイボテク・フアーマシユーチカルズ Ｈｉｖ阻害性５−置換ピリミジン
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
US20080139531A1 (en) 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
WO2008132505A1 (en) 2007-04-27 2008-11-06 Astrazeneca Ab N' - (phenyl) -n- (morpholin-4-yl-pyridin-2-yl) -pyrimidine-2, 4-diamine derivatives as ephb4 kinase inhibitors for the treatment of proliferative conditions
EA201000101A1 (ru) 2007-07-16 2010-08-30 Астразенека Аб Производные пиримидина 934
CN101903357A (zh) 2007-07-17 2010-12-01 里格尔药品股份有限公司 作为pkc抑制剂的环状胺取代的嘧啶二胺
SG165655A1 (en) 2008-04-16 2010-11-29 Portola Pharm Inc 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
HRP20161310T1 (hr) 2008-04-16 2016-12-02 Portola Pharmaceuticals, Inc. 2,6-diamino-pirimidin-5-il-karboksamidi kao inhibitori syk ili jak kinaza
AU2009238590A1 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
PE20100087A1 (es) 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
JP5644499B2 (ja) 2008-09-01 2014-12-24 アステラス製薬株式会社 ２，４−ジアミノピリミジン化合物
US20110166161A1 (en) 2008-09-18 2011-07-07 Astellas Pharma Inc. Heterocyclic carboxamide compounds
TW201016676A (en) 2008-10-03 2010-05-01 Astrazeneca Ab Heterocyclic derivatives and methods of use thereof
US9234178B2 (en) 2008-10-31 2016-01-12 Janssen Biotech, Inc. Differentiation of human pluripotent stem cells
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
EP2375899B1 (en) 2009-01-12 2015-02-25 Array Biopharma Inc. Piperidine-containing compounds and use thereof in the treatment of diabetes
US8470835B2 (en) 2009-01-13 2013-06-25 Glaxo Group Limited Pyrimidinecarboxamide derivatives as inhibitors of Syk kinase
JP5781943B2 (ja) 2009-01-21 2015-09-24 ライジェル ファーマシューティカルズ， インコーポレイテッド 炎症性疾患、自己免疫疾患または増殖性疾患の治療に有用なｎ２−（３−ピリジルまたはフェニル）−ｎ４−（４−ピペリジル）−２，４−ピリミジンジアミン誘導体
US8450363B2 (en) * 2009-02-06 2013-05-28 Elan Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
US8367689B2 (en) 2009-05-06 2013-02-05 Portola Pharmaceuticals, Inc. Inhibitors of JAK
LT3009428T (lt) 2009-05-08 2018-04-10 Astellas Pharma Inc. Diamino heterociklinis karboksamido junginys
EP2440548A1 (en) 2009-06-10 2012-04-18 Abbott Laboratories 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors
JP2012197231A (ja) 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
WO2011065800A2 (ko) 2009-11-30 2011-06-03 주식회사 오스코텍 피리미딘 유도체, 이의 제조방법 및 이를 함유하는 약학적 조성물
EP2507227B1 (en) 2009-12-01 2014-10-08 Rigel Pharmaceuticals, Inc. Tetrazolones as protein kinase c inhibitors and uses thereof
JP6035238B2 (ja) 2010-07-21 2016-11-30 ライジェル ファーマシューティカルズ， インコーポレイテッド プロテインキナーゼｃ阻害剤およびその使用
US8580805B2 (en) 2010-08-31 2013-11-12 Hubert Maehr Pyrimidine carboxamide derivatives
EP2621489A1 (en) 2010-09-30 2013-08-07 Portola Pharmaceuticals, Inc. Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine
WO2012044936A1 (en) 2010-09-30 2012-04-05 Portola Pharmaceuticals, Inc. Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
US8680076B2 (en) 2010-10-25 2014-03-25 Signal Pharmaceuticals, Llc Methods of treatment, improvement and prevention using haloaryl substituted aminopurines
US9139534B2 (en) * 2011-04-22 2015-09-22 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
US9512124B2 (en) 2014-10-06 2016-12-06 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
CN107108524A (zh) 2014-12-16 2017-08-29 西格诺药品有限公司 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物

Similar Documents

Publication Publication Date Title
Bousquet et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber
JP2018500560A5 (https=)
TWI791507B (zh) 使用ccr3-抑制劑治療老化相關損傷之方法及組合物
US20170143723A1 (en) Pharmaceutical combinations
CA3210612C (en) Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
JP2025065545A (ja) 特定の患者集団において神経変性障害を処置する方法
JP2020002179A (ja) 多発性骨髄腫を治療するための薬物の組み合わせ
CN107427502A (zh) 使用川地匹坦的治疗方法
US11779572B1 (en) Methods of treating gastrointestinal stromal tumors
US20220008414A1 (en) Pharmaceutical composition comprising histone deacetylase 6 inhibitors
CN107810002A (zh) 左乙拉西坦的延时释放药物组合物
KR20180082564A (ko) Nash의 치료 또는 예방을 위한 의약 조성물
JP2023036694A (ja) 皮膚におけるｃ－Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法
US20190240211A1 (en) Combination of pimavanserin and cytochrome p450 modulators
JP2019513762A (ja) 胆汁うっ滞及び線維症の処置方法
US10722526B2 (en) Pharmaceutical compositions for radioprotection or radiomitigation and methods for using them
JP2014534229A (ja) 骨髄増殖性新生物形成および慢性骨髄性白血病を含む、トランスデューシンβ様タンパク質１（ＴＢＬ１）活性に関連する疾患および障害の処置のための方法
CN115350182B (zh) Wz4141或其药学上可接受的盐在制备治疗或缓解炎症药物中的用途
CN112105598B (zh) 用于预防或治疗肥胖或代谢综合征的化合物和包含其的药学组合物
TW202042804A (zh) 使用lta4h抑制劑治療化膿性汗腺炎之方法
TW201323425A (zh) 抗菌性咔啉化合物
CN112672742B (zh) 纤维化治疗用医药组合物
JP7283699B2 (ja) 黒色腫の治療または予防において使用するためのフェニル－ヘテロ環－フェニル誘導体
JP2022522873A (ja) レボケトコナゾールによる疾患の処置方法
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3